Health Economics›Non-small cell lung cancer›Advanced or metastatic disease previously treated BRAF inhibitor-naive

Advanced or metastatic disease previously treated BRAF inhibitor-naive

Non-small cell lung cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	~10.7 mo	—	~12	~R 633 492 PFS proxy · indirect	6
Binimetinib and Encorafenib Variant #01 Partial	BRAF	—	28d	~14.9 mo	~33.6 mo	~17	—	2

2 of 2 regimens shown